Collaboration agreement
Pasteur Institute spin-out Celogos, of Paris, France and Stem Cell Sciences KK of Kobe, Japan, reached an agreement on the licensing of technologies for cell implants for the treatment of urinary stress incontinence.
Celogos has granted exclusive rights to commercialise products based on its Rational Cell Design (RCD) technology platform that can be used to develop, optimise, produce and implant novel cells to Stem Cell Sciences KK for the Japanese market.
The therapy for urinary incontinence is currently in phase I/II clinical trials in France. RCD technologies have enabled Celogos to establish a complete process for myoblast implantation, from removal of muscular tissue biopsy, cell-isolation and cultivation, to implantation into the urethral sphincter.
This new technology from Celogos will provide Stem Cell Sciences KK, a subsidiary of Stem Cell Sciences plc of Edinburgh, with a more clinically advanced product to expand and diversify its cell therapy pipeline.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
